FWM
ENTA icon

Focused Wealth Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Focused Wealth Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-287
Closed -$24K – 719
2019
Q2 		$24K Buy
+287
New +$25.8K 0.01% 394

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Focused Wealth Management's ENTA Position: Q3 2019 in Review

Focused Wealth Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 287 shares — an estimated $24K sold.

Focused Wealth Management first reported a position in ENTA in Q2 2019 and held it in 1 quarter. The position peaked at $24K in Q2 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • Focused Wealth Management reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Focused Wealth Management sold 287 Enanta Pharmaceuticals shares in Q3 2019, an estimated $24K.
  • Focused Wealth Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • Focused Wealth Management's Enanta Pharmaceuticals position peaked at $24K in Q2 2019.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Focused Wealth Management's 13F filing for Q3 2019, filed 6 Nov 2019.